Board Changes

CRISM Therapeutics Corporation

02 April 2026

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

2 April 2026

CRISM Therapeutics Corporation

('CRISM', 'CRISM Therapeutics' or the 'Company')

Board Changes

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that Dr Nermeen Varawalla has resigned from the Board of Directors in order to pursue other professional interests.  Nermeen was appointed Non-Executive Chair at the Company's Admission to AIM in May 2024 and, as previously announced, in October 2025 stepped back from her role. 

Andrew Webb will continue to act as Executive Chair on an interim basis until a new Chair is identified. Gerry Beaney, Independent Non-Executive Director and Chair of the Audit Committee will chair the Remuneration Committee.

Andrew Webb, Interim Exec Chair, said: "The Company wishes to thank Nermeen for her valuable contribution to CRISM since our AIM listing in May 2024 and we wish her well with her future endeavours.  A search for a successor with the requisite skills and experience as CRISM progresses towards its phase 2 clinical trial and future commercialisation is underway. We will update the market as to its progress in due course."  

-Ends-

Enquiries:

Company	Nomad and Broker	Financial PR
CRISM Therapeutics Corporation	S.P. Angel Corporate Finance LLP	Burson Buchanan
Andrew Webb, Interim Exec Chair Chris McConville, CSO	Richard Morrison Vadim Alexandre Adam Cowl	Henry Harrison Topham / Jamie Hooper [e-mail]
via Burson Buchanan	[phone]	[phone]

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

For more information please visit: https://www.crismtherapeutics.com/

The Company's LEI is 213800XFW6MKVCHHPW88.

 

END